EIGR vs. WINT, NMTR, ENVB, MBIO, LUCY, CWBR, DYNT, QNRX, ONCO, and CYTO
Should you be buying Eiger BioPharmaceuticals stock or one of its competitors? The main competitors of Eiger BioPharmaceuticals include Windtree Therapeutics (WINT), 9 Meters Biopharma (NMTR), Enveric Biosciences (ENVB), Mustang Bio (MBIO), Innovative Eyewear (LUCY), CohBar (CWBR), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), Onconetix (ONCO), and Altamira Therapeutics (CYTO). These companies are all part of the "medical" sector.
Eiger BioPharmaceuticals (NASDAQ:EIGR) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.
Eiger BioPharmaceuticals presently has a consensus target price of $120.00, suggesting a potential upside of 6,856.52%. Given Eiger BioPharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eiger BioPharmaceuticals is more favorable than Windtree Therapeutics.
Eiger BioPharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.
In the previous week, Windtree Therapeutics had 2 more articles in the media than Eiger BioPharmaceuticals. MarketBeat recorded 4 mentions for Windtree Therapeutics and 2 mentions for Eiger BioPharmaceuticals. Eiger BioPharmaceuticals' average media sentiment score of 0.12 beat Windtree Therapeutics' score of 0.00 indicating that Eiger BioPharmaceuticals is being referred to more favorably in the media.
Windtree Therapeutics has lower revenue, but higher earnings than Eiger BioPharmaceuticals. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
62.5% of Eiger BioPharmaceuticals shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 4.2% of Eiger BioPharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Windtree Therapeutics has a net margin of 0.00% compared to Eiger BioPharmaceuticals' net margin of -590.80%. Windtree Therapeutics' return on equity of -275.06% beat Eiger BioPharmaceuticals' return on equity.
Eiger BioPharmaceuticals received 411 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 67.65% of users gave Eiger BioPharmaceuticals an outperform vote while only 50.00% of users gave Windtree Therapeutics an outperform vote.
Summary
Eiger BioPharmaceuticals beats Windtree Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Eiger BioPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EIGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eiger BioPharmaceuticals Competitors List
Related Companies and Tools
